Neuromyelitis Optica Spectrum Disorder (NMOSD) – Current Treatment – Current Treatment: Physician Insights – Neuromyelitis Optica Spectrum Disorder (US)

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, chronic autoimmune neuroinflammatory disorder marked by optic neuritis and longitudinally extensive transverse myelitis, often leading to repeated attacks and progressive neurological damage. Recent advancements have led to the development of targeted therapies such as Alexion Pharmaceuticals’ Soliris and Ultomiris, Roche / Genentech’s Enspryng and Amgen’s Uplizna, which is specifically approved for AQP4-positive NMOSD. However, owing to high costs, access considerations, and individualized, patient-specific treatment decision-making, off-label agents such as rituximab, corticosteroids, and immunosuppressants are widely used, particularly in early treatment stages and among patients with AQP4-seronegative disease, for whom approved options are limited. Ongoing research aims to develop effective therapies for seronegative patients, generate long-term safety and efficacy data, and identify predictive biomarkers to further improve NMOSD management.

Questions answered

• How does physician prescribing of current treatment options vary based on their antibody status, i.e., for AQP4-positive and seronegative patients?
• What is the patient share of key therapies, including approved monoclonal antibodies, Soliris, Ultomiris, Enspryng, and Uplizna, in the United States, according to surveyed neurologists?
• What are the clinical characteristics that physicians consider when choosing each biologic for their AQP4-positive NMOSD patients?
• What are the key drivers and obstacles determining current prescribing patterns in the treatment of NMOSD patients?

Geography: United States

Primary research: Survey of 100 U.S. neurologists

Key drugs covered: Enspryng (satralizumab), rituximab, Soliris (eculizumab), Uplizna (inebilizumab), Ultomiris (ravulizumab)

Key analyses

• Factors influencing disease management and treatment decisions
• Drivers and constraints of treatment selection
• Physician-reported treatment practices and brand-level patient shares
• Rationale for changes in treatment approach
• Physician insight on persistency and compliance

Product description

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.